Le Lézard
Classified in: Covid-19 virus
Subject: OBI

Long Island Law Firm Announces Continuation Following Founder's Death due to COVID


COMMACK, N.Y., Sept. 24, 2020 /PRNewswire-PRWeb/ -- The Law Firm of Rudolph F. X Migliore, P.C. announces the passing of its founder Rudolph F.X Migliore due to complications from COVID-19. During this transition, the firm welcomes Rudolph's son, Rudolph J. Migliore, as the new President and Lead Attorney. In addition, the firm welcomes Rudolph's second son, Matthew Migliore, as the new Operations Coordinator. The Law Firm of Rudolph F. X Migliore, P.C. assures that the firm's mission and values will remain the same. The firm stands ready to assist clients with all their legal needs. The firm is joined with a nationwide network of co-counsel providing powerful representation while also providing local, personal service to its clients.

The late Rudolph F.X. Migliore said "Our attorneys recognize that people suffer a great deal of disability and pain as a result of defective products. Our goal is to protect their legal rights and interests as they seek to recover compensation for their injuries." The Law Firm of Rudolph F. X Migliore, P.C will continue to actively serve and help the community while seeking justice to assist our clients' needs.

The Law Firm of Rudolph F.X. Migliore, P.C. is a full-service firm, providing a wide variety of legal services to victims of Asbestos, Mesothelioma, Lung Cancer, Personal Injury, Nursing Home Negligence, Labor Law and Product Liability. Mr. Migliore's sons will continue to be actively involved with the community and serve as a resource to non-profit organizations, churches, and ministries.

Rudolph F.X. Migliore, P.C.
353 Veterans Memorial Highway
Suite 200
Commack, NY 11725    
(631) 543-3663
http://www.Migliorelaw.com
Visit us on Facebook

 

SOURCE Rudolph F.X. Migliore, P.C.


These press releases may also interest you

at 16:05
CACI International Inc , a leading provider of expertise and technology to government customers, announced results today for its fiscal third quarter ended March 31, 2024. "CACI's outstanding performance reflects the continued successful execution...

at 16:05
Arrowhead Pharmaceuticals, Inc. today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and...

at 16:05
Dynavax Technologies Corporation , a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close....

at 16:05
-- Europe transaction closed on April 1st; expected to deliver $750M+ net present value of future cash flows and $250-$300M incremental cash flow in 2025 -- Strong Q1 performance from Latin America, Asia, and SDA Global driven by share gains and cost...

at 16:01
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of...

at 16:00
Allergy & Asthma Network, the leading nonprofit outreach, education, advocacy and research organization for adults and children living with asthma, allergies and related conditions, announces its Trusted Messengers program community outreach plans...



News published on and distributed by: